1例低剂量表柔比星致重度急性左心衰患者的药学监护

doi:10.19803/j.1672-8629.2021.12.20

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (12): 1189-1191.
DOI: 10.19803/j.1672-8629.2021.12.20

1例低剂量表柔比星致重度急性左心衰患者的药学监护

李黎, 张丹, 周楠, 张鹏, 朱亚宁^*

陕西省人民医院,陕西西安 710068

收稿日期:2020-03-30 出版日期:2021-12-15 发布日期:2021-12-16
通讯作者: ^*朱亚宁,女,硕士,副主任药师,临床药学。E-mail：zhuyn2235@163.com
作者简介:李黎,女,硕士,临床药学。
基金资助:
国家自然科学基金青年科学基金资助（81703514）

Pharmaceutical Care of One Patient with Severe Acute Left Heart Failure Induced by Low-dose Epirubicin

LI Li, ZHANG Dan, ZHOU Nan, ZHANG Peng, ZHU Yaning^*

Shaanxi Provincial People's Hospital, Xi'an Shaanxi 710068, China

Received:2020-03-30 Online:2021-12-15 Published:2021-12-16

摘要/Abstract

摘要： 目的通过参与1例低剂量表柔比星致重度急性左心衰患者的治疗过程,探讨临床药师对化疗患者进行不良反应监护的重要性。方法临床药师从化疗药物方案调整、不良反应相关性和发生不良反应的危险因素等多方面进行分析,对累积剂量仅为51 mg/m²的表柔比星所致严重心衰患者的诊疗过程进行全面的药学监护。结果临床药师协助医师及时判断和处理不良反应,分析潜在危险因素,保证了后续化疗的顺利进行。结论蒽环类药物没有绝对的“安全剂量”,临床药师能够协助医师全程监护化疗患者,避免严重不良反应的发生。

关键词: 表柔比星, 急性左心衰, 药品不良反应, 药学监护

Abstract: Objective To study the importance of clinical pharmacists monitoring adverse reactions among patients under chemotherapy by reviewing the process of treating one patient with severe acute left heart failure induced by low-dose epirubicin.Methods Clinical pharmacists participated in the adjustment of chemotherapy drugs, made correlation analysis, analyzed the risk factors for adverse reactions, and conducted comprehensive pharmaceutical monitoring for a patient with severe heart failure caused by epirubicin at a cumulative dose of only 51 mg/m². Results Clinical pharmacists assisted physicians in making quick judgment and dealing with adverse reactions, analyzed potential risk factors, and removed obstacles to subsequent chemotherapy.Conclusion Anthracyclines have no absolute“safe dose”. Clinicians have to be alert to serious adverse reactions in elderly patients with liver dysfunction, hypoproteinemia, hypercalcemia, and low body weight. Clinical pharmacists can help physicians monitor patients under chemotherapy to prevent serious adverse reactions.

Key words: epirubicin, acute left heart failure, adverse drug reaction, pharmaceutical care

中图分类号:

R969.3

李黎, 张丹, 周楠, 张鹏, 朱亚宁. 1例低剂量表柔比星致重度急性左心衰患者的药学监护[J]. 中国药物警戒, 2021, 18(12): 1189-1191.

LI Li, ZHANG Dan, ZHOU Nan, ZHANG Peng, ZHU Yaning. Pharmaceutical Care of One Patient with Severe Acute Left Heart Failure Induced by Low-dose Epirubicin[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1189-1191.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.2021.12.20

https://zgywjj.magtechjournal.com/CN/Y2021/V18/I12/1189

参考文献

[1] Siegel RL, Fedewa SA, Miller KD, et al.Cancer statistics for Hispanics/Latinos[J]. CA Cancer J Clin, 2015, 65(6): 457-480.
[2] CSCO, CHS.Expert consensus of preventing heart toxicity by anthracycline in China(version 2013)[J]. Chinese Clinical Oncology(临床肿瘤学杂志), 2013, 18(10): 925-934
[3] Banke A, Fosbøl EL, Møller JE, et al.Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial[J]. Eur J Heart Fail, 2018, 20(10): 1447-1453.
[4] Narod SA, Dent RA, Foulkes WD.CCR 20th anniversary commentary:triple-negative breast cancer in 2015-Still in the Ballpark[J]. Clin Cancer Res, 2015, 21(17): 3813-3814.
[5] Sun Y, Shi YK.Handbook of Clinical Oncology(临床肿瘤内科手册)[M]. 5th ed. Beijing: People's Medical Publishing House, 2013: 433.
[6] Wojnowski L, Kulle B, Schirmer M, et al.NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity[J]. Circulation, 2005, 112(24): 3754-3762.
[7] Simunek T, sterba M, Popelova O, et a1. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron[J]. Pharmacol Rep, 2009, 61(1): 154-171.
[8] Yang M, Lu J, Mu JJ, et al.A systematic review of Shengmai injection in the prevention and treatment of cardiotoxicity of anthracycline antitumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2012, 9(11): 666-669.
[9] Shi Y, Fan DF, Hou BL, et al.The mechanism of action of adriamycin-induced cardiotoxicity and research progress in prevention and treatment of traditional Chinese medicine[J]. Xinjiang Journal of Traditional Chinese Medicine(新疆中医药), 2019, 37(1): 113-116.
[10] Drafts BC, Twomley KM, D"Agostino R, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease[J]. JACC Cardiovasc Imag, 2013, 6(8): 877-885.
[11] Su HG.Adverse reactions and influencing factors in the application of tumor chemotherapy drugs[J]. Chinese Journal of Modern Drug Application(中国现代药物应用), 2017, 11(9): 108-110.
[12] Zhai SJ.Observation on the characteristics and risk factors of heart failure in critically ill patients[J].Electronic Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Diseases(中西医结合心血管病电子杂志), 2019, 7(2): 48.
[13] Lauritsen J, Gustafsson F, Abdulla J.Characteristics and Long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis[J]. ESC Heart Fail, 2018, 5(4): 685-694.
[14] Li P.The influence of BMI index on the prognosis of patients with chronic heart failure after myocardial infarction[D]. Taiyuan: Shanxi Medical University, 2019.
[15] Arun B, Akar U, Gutierrez-Barrera AM, et al.The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA 1 and BRCA 2 mutant breast cancer cells[J]. Int J Oncol, 2015, 47(1): 262-268.
[16] Wang HL. Clinical Pharmacology(临床药理学)[M]. Beijing: Higher Education Press, 2015: 33.

1例低剂量表柔比星致重度急性左心衰患者的药学监护

Pharmaceutical Care of One Patient with Severe Acute Left Heart Failure Induced by Low-dose Epirubicin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[2]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[3]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[4]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[5]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.
[6]	陈桦宝, 刘薇, 蒋婷, 郑玲利, 李静. 盐酸纳洛酮注射液致急性戒断综合征1例分析[J]. 中国药物警戒, 2025, 22(8): 944-946.
[7]	杨欣, 杨宝春, 杨漾, 邵欢. 信迪利单抗致内分泌系统不良反应1例分析[J]. 中国药物警戒, 2025, 22(8): 947-949.
[8]	王春婷, 陈亚飞, 李婷婷. 化学药品上市后说明书安全信息修订考虑要点[J]. 中国药物警戒, 2025, 22(7): 776-779.
[9]	朱会卷, 任经天. 狂犬病人免疫球蛋白安全性风险分析[J]. 中国药物警戒, 2025, 22(7): 786-789.
[10]	陈耀哲, 詹云丽, 宋兴栋, 朱漫玉, 欧雪媚, 李楚云. 48例哌拉西林钠他唑巴坦钠血液系统不良反应分析[J]. 中国药物警戒, 2025, 22(7): 794-798.
[11]	曹凯, 钱佩佩, 高鑫, 杨付田, 赵亮, 徐炳欣, 张现军. 基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析[J]. 中国药物警戒, 2025, 22(7): 799-804.
[12]	林璐, 赵安职, 陈锦辉, 李忠文, 黄国华, 钟诗龙. 注射用头孢噻肟钠舒巴坦钠致迟发型超敏反应1例分析[J]. 中国药物警戒, 2025, 22(7): 809-811.
[13]	唐炯, 曾语琦. 舒格利单抗注射液致动眼神经麻痹1例分析[J]. 中国药物警戒, 2025, 22(7): 812-814.
[14]	王媛, 李若柠, 郭展立, 张磊, 李嘉媛, 冬颖, 孙建军. 替罗非班注射液致极重度血小板减少症1例分析[J]. 中国药物警戒, 2025, 22(7): 815-818.
[15]	雷建林, 王娜, 王文筝, 王岩. 复方妥英麻黄茶碱片致苯妥英钠中毒1例分析[J]. 中国药物警戒, 2025, 22(7): 819-822.